AU2470595A - Compositions and treatment for multiple sclerosis - Google Patents

Compositions and treatment for multiple sclerosis

Info

Publication number
AU2470595A
AU2470595A AU24705/95A AU2470595A AU2470595A AU 2470595 A AU2470595 A AU 2470595A AU 24705/95 A AU24705/95 A AU 24705/95A AU 2470595 A AU2470595 A AU 2470595A AU 2470595 A AU2470595 A AU 2470595A
Authority
AU
Australia
Prior art keywords
peptide
mbp
amino acid
acid residues
human mbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24705/95A
Other languages
English (en)
Inventor
Di-Hwei Hsu
Jia Dong Shi
Dawn Smilek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Original Assignee
Immulogic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp filed Critical Immulogic Pharmaceutical Corp
Publication of AU2470595A publication Critical patent/AU2470595A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU24705/95A 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis Abandoned AU2470595A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24124694A 1994-05-10 1994-05-10
US241246 1994-05-10
US32822494A 1994-10-25 1994-10-25
PCT/US1995/005605 WO1995030435A2 (en) 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis
US328224 2002-12-23

Publications (1)

Publication Number Publication Date
AU2470595A true AU2470595A (en) 1995-11-29

Family

ID=26934122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24705/95A Abandoned AU2470595A (en) 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis

Country Status (11)

Country Link
EP (1) EP0758902A1 (ja)
JP (1) JPH10500109A (ja)
AU (1) AU2470595A (ja)
CA (1) CA2189990A1 (ja)
CZ (1) CZ329596A3 (ja)
HU (1) HUT76099A (ja)
IL (1) IL113661A0 (ja)
PL (1) PL317197A1 (ja)
SI (1) SI9520059A (ja)
SK (1) SK145896A3 (ja)
WO (1) WO1995030435A2 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT77047A (hu) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
AU5671196A (en) * 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
EP0939826A2 (en) * 1996-08-15 1999-09-08 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
CN102784385B (zh) * 2000-08-21 2015-11-25 阿皮托普技术(布里斯托尔)有限公司 肽选择方法
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
CN1656222B (zh) 2002-03-27 2011-11-30 艾格拉治疗公司 反义iap核碱基寡聚物及其应用
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212358T1 (de) * 1992-04-09 2002-02-15 Autoimmune Inc Unterdrückung der proliferation von t-zellen mittels peptidfragmenten des basischen proteins aus myelin
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease

Also Published As

Publication number Publication date
WO1995030435A2 (en) 1995-11-16
CA2189990A1 (en) 1995-11-16
EP0758902A1 (en) 1997-02-26
CZ329596A3 (en) 1997-05-14
SK145896A3 (en) 1997-05-07
PL317197A1 (en) 1997-03-17
HUT76099A (en) 1997-06-30
JPH10500109A (ja) 1998-01-06
WO1995030435A3 (en) 1995-12-07
SI9520059A (en) 1997-08-31
IL113661A0 (en) 1995-08-31
HU9603116D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
EP0553291B1 (en) Treatment of autoimmune diseases by oral administration of autoantigens
EP0359783B2 (en) Treatment of autoimmune diseases by oral administration of autoantigens
US5733547A (en) Treatment of autoimmune arthritis by oral administration of type I or type III collagen
US5869054A (en) Treatment of multiple sclerosis by oral administration of autoantigens
AU2470595A (en) Compositions and treatment for multiple sclerosis
US5756449A (en) Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
US10363306B2 (en) Cytokines and neuroantigens for treatment of immune disorders
CA2203629A1 (en) Compositions and treatment for multiple sclerosis
JP2004026797A (ja) ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
CA2133749A1 (en) Suppression of t-cell proliferation using peptide fragments of myelin basic protein
US6180103B1 (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
US6265374B1 (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
Jung et al. Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN.
AU684713B2 (en) Peptide T and related peptides in the treatment of inflammatory bowel disease
US20230172894A1 (en) Combination treatment for fumarate-related diseases
RU2130317C1 (ru) Линейные или циклические пептиды, их применение, способ лечения